Public Release: 

New hope for HIV sufferers

Immunosuppressant delays AIDS onset

BioMed Central

A drug that suppresses the immune system delays the onset of AIDS in patients with HIV, according to a study published this week in BMC Medicine. Prednisolone, taken without any antiviral therapy, postponed the loss of T-cells that leads to AIDS in 50% of HIV sufferers by between 2 and 10 years.

HIV leads to a complex disorder that combines an initial chronic activation of the immune system with a progressive decrease in the number of CD4+ T cells, which are involved in the immune response. If the number of CD4+ T cells falls below a certain level, the weakened immune system is less able to fight infections and the symptoms of AIDS develop.

Rejecting the commonly accepted view that the CD4+ T cells are killed solely by the HIV virus, Jean-Marie Andrieu and Wei Lu of Université René Descartes in Paris believe that the hyperactivity of the immune system is part of the problem. To test whether reducing the activity of the immune system can protect patients' CD4+ T-cell numbers and hence delay AIDS onset, the researchers initiated a trial where 44 patients with HIV were given the immunosuppressant drug, prednisolone.

After two years of taking the drug, 50% of patients had CD4+ T-cell counts higher than they did at the start of the trial. This compares with 5% of patients that did not take prednisolone.

After five years, more than 10% of the patients taking prednisolone had higher CD4+ T-cell counts than they did at the start of the trial, compared with virtually no patients in the control group.

Prednisolone was particularly effective at maintaining high CD4+ T-cell counts and delaying AIDS onset in patients that initially had a low level of virus in their body. Importantly, despite suppressing patients' immune response, prednisolone did not cause the HIV virus to replicate more vigorously.

Prednisolone is a very inexpensive drug belonging to the class of glucocorticoids. The side effects of the drug were mild at the low daily dose at which it was given.

The authors expect their study to prompt further clinical trials. These should test different doses of prednisolone or other glucocorticoids, to define the lowest dose that can maintain the population of CD4+ T-cells. In addition, researchers could investigate whether the antiretroviral therapy for AIDS, HAART, is more effective if given in conjunction with glucocorticoids.


This press release is based on the following article:

Long-term clinical, immunologic and virologic impact of glucocorticoids on the chronic phase of HIV infection
Jean-Marie Andrieu and Wei Lu
BMC Medicine 2004, 2:17

To be published on 5 May 2004

Upon publication this article will be available free of charge according to BMC Medicine's Open access policy via:

Please quote the journal name in any story you write, and link to the article if you are writing for the web.


For further information about this research, please contact Jean-Marie Andrieu by email at: or by phone on 33-6-85-81-87-67 or 33-1-56-09-34-71

Alternatively, or for more information about BMC Medicine or Open Access publishing contact Gemma Bradley by phone on 44-207-323-0323 or by email at


BMC Medicine ( publishes original research articles, technical advances and study protocols in any area of medical science or clinical practice. To be appropriate for BMC Medicine, articles need to be of special importance and broad interest.

BMC Medicine is published by BioMed Central (, an independent online publishing house committed to providing Open Access to peer-reviewed biological and medical research. This commitment is based on the view that immediate free access to research and the ability to freely archive and reuse published information is essential to the rapid and efficient communication of science. BioMed Central currently publishes over 100 journals across biology and medicine. In addition to open-access original research, BioMed Central also publishes reviews, commentaries and other non-original-research content. Depending on the policies of the individual journal, this content may be open access or provided only to subscribers.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.